Matricelf Ltd. MTLF

CHARLOTTE, N.C., September 10, 2026--Zero Networks, the leading provider of Zero Trust security solutions, today announced the appointment of Yossi Dagan as Chief Financial Officer (CFO), further strengthening its executive leadership team as the company scales its global business and continues to see growing enterprise demand for automated microsegmentation.

Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing a personalized, autologous neural tissue transplant for the treatment of spinal cord injury, today announced that it has received written feedback from the U.S. Food and Drug Administration, FDA, Center for Biologics Evaluation and Research, CBER, regarding the proposed design of the Company's first in human clinical trial of NewRal.

Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized, autologous engineered neural tissue for the treatment of spinal cord injury (SCI), today announced that it has received approval from the Helsinki Committee (Institutional Review Board) and the Director of Loewenstein Rehabilitation Medical Center, Israel's leading rehabilitation hospital and one of the country's premier referral centers for spinal cord injury, to begin collecting blood samples from eligible pa

Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered tissue implants for spinal cord injury, announced the initiation of a pivotal preclinical efficacy study evaluating its engineered human neural tissue implant for the treatment of chronic spinal cord injury. The study is designed to generate efficacy data supporting the Company's preparations for a first in human clinical trial.

Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered tissue implants for spinal cord injury, today announced the successful completion of its comprehensive GLP safety study for its engineered neural tissue implant, achieving all predefined study endpoints with no abnormal findings.

– Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered tissue implants for spinal cord injury, today announced the initiation of GMP manufacturing activities at Sheba Medical Center's Advanced Biotherapy Center, marking a significant milestone in the Company's transition toward clinical development.

Matricelf Ltd. (TASE: MTLF), a biotechnology company developing a novel autologous engineered neural tissue therapy for patients with spinal cord injury, today announced it has entered into a Collaborative Research Agreement with the CiRA Foundation, a global leader in induced pluripotent stem cell (iPSC) research and regenerative medicine.

Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing autologous engineered neural tissue therapies, today announced a strategic collaboration with Sheba Medical Center, Tel Hashomer, ranked 7th globally by Newsweek, to support the execution of its first in human clinical trial in spinal cord injury.

Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered neural tissue implants for the treatment of spinal cord injury, today announced positive results from advanced RNA sequencing analyses of its human tissue implant, supporting key safety characteristics required for progression toward clinical trials.

Matricelf Ltd. (TASE: MTLF), a biotechnology company developing autologous engineered tissue therapies, today announced the appointment of Mr. Ron Mayron as Active Chairman of the Board of Directors. Mr. Mayron's appointment follows shareholder approval and submission of his formal Director Eligibility Declaration in accordance with the Israeli Companies Law.

Matricelf Ltd. (TASE: MTLF), a biotechnology company developing personalized regenerative therapies for spinal cord injury, today issued a shareholder update summarizing its 2025 achievements and outlining key strategic milestones for 2026 and beyond.

The Middle Eastern stock markets have recently seen a rise, buoyed by increasing oil prices and global market optimism ahead of the U.S. Federal Reserve's policy meeting. For investors looking beyond the well-known names, penny stocks can present intriguing opportunities, especially when they are supported by solid financials. While the term "penny stocks" might seem outdated, these smaller or newer companies continue to offer potential for growth and value that larger firms may not always...